MEI Pharma, Inc.
3611 Valley Centre Drive, Suite #500
About MEI Pharma, Inc.
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in Phase II clinical studies for advanced hematologic diseases. The Company is also developing ME-344, a novel mitochondrial inhibitor that has shown evidence of clinical activity in refractory solid tumors, and ME-401 (formerly PWT143), a highly selective, oral PI3K delta inhibitor. For more information, please visit www.meipharma.com.
CEO: Daniel Gold, PhD
Please click here for clinical trial information.
Please click here for Mei Pharma job opportunities.
289 articles with MEI Pharma, Inc.
Marshall Edwards, Inc. To Present At The CIBC World Markets Annual Biotechnology And Specialty Pharmaceuticals Conference
Yale University Researchers Find Phenoxodiol Restores Sensitivity To Chemotherapy In Some Women With Ovarian, Fallopian Tube Or Primary Peritoneal Cancer, In Interim Report On A Phase II Study
Marshall Edwards, Inc. Release: New Clinical Study Of Phenoxodiol As Chemo-sensitizer For Docetaxel In Ovarian Cancer Commences At Yale University School Of Medicine
Marshall Edwards, Inc. Release: Researchers Report That Phenoxodiol Produces Anti-Cancer Responses In Women With Cervical Cancer
Marshall Edwards, Inc. Release: Phenoxodiol Delays Tumor Progression In Late-Stage Hormone Refractory Prostate Cancer
Marshall Edwards, Inc. Release: Researchers Report That Phenoxodiol Is Producing Significant Anti-Cancer Responses In Women With Gynecological Cancers